| Literature DB >> 32919573 |
Weihua Jin1, Xinyue He2, Jiachen Zhu2, Qiufu Fang2, Bin Wei3, Jiadong Sun4, Wenjing Zhang5, Zhongshan Zhang6, Fuming Zhang7, Robert J Linhardt8, Hong Wang9, Weihong Zhong10.
Abstract
The anti-lung cancer activity of oligosaccharides derived from glucuronomannan was investigated. The inhibition of A549 cell proliferation by glucuronomannan (Gn) and its oligomers (dimer (G2), tetramer (G4) and hexamer (G6)) were concentration dependent. In vivo activities on the A549-derived tumor xenografts showed the tumor inhibition of G2, G4 and G6 were 17 %, 40 % and 46 %, respectively. Organ coefficients in nude mice showed an increase in the kidney with G4, the brain with G6, and the spleen with G6. An advanced tandem mass tag labeled proteomics approach was performed. A significant differential expression was found in 59 out of the 4371 proteins, which involved the immune system. Surface plasmon resonance (SPR) studies revealed G6 was strongly bound to immunoglobulin G. This suggests that glucuronomannan hexamer inhibits the proliferation of lung cancer through its binding to immunoglobulin.Entities:
Keywords: Anti-lung cancer activity; Fucoidan; Glucuronomannan; Proteomics; SPR
Mesh:
Substances:
Year: 2020 PMID: 32919573 DOI: 10.1016/j.carbpol.2020.116785
Source DB: PubMed Journal: Carbohydr Polym ISSN: 0144-8617 Impact factor: 9.381